DRI Healthcare Trust Is Maintained at Outperform by Scotiabank
Strong Buy Rating for DRI Healthcare Trust on Strategic Acquisition and Market Undervaluation
Dri Healthcare Trust Price Target Raised to C$23.00/Share From C$20.00 by Raymond James
Dri Healthcare Trust Price Target Cut to C$14.00/Share From C$17.00 by Truist Securities
DRI Healthcare Trust Downgraded to Hold as CEO Fired Amid an Investigation; Price Target Cut to C$15.00
DRI Healthcare Price Target Lowered to $18.50 at CIBC
RBC Capital Reiterates Outperform on DRI HEALTHCARE TRUST, Maintains C$20 Price Target
National Bank Highlights Key Takeaways From DRI Healthcare Trust's Investor Meetings; Raises Price Target
RBC Capital Reiterates Outperform on DRI HEALTHCARE TRUST, Maintains C$18 Price Target
DRI Healthcare Trust Maintains Buy Rating From Stifel GMP as It Adds a New Drug Royalty; Price Target Kept at C$20.00
RBC Capital Maintains Outperform on DRI Healthcare Trust, Raises Price Target to C$18
DRI Healthcare Trust Price Target Raised to $18 at Raymond James
DRI Healthcare Trust Initiated at Buy at Stifel GMP; Price Target Set at C$20.00
Truist Securities Maintains Buy on DRI Healthcare Trust, Raises Price Target to C$14
RBC Capital Maintains Outperform on DRI Healthcare Trust, Raises Price Target to C$17
Raymond James Initiates Coverage On DRI Healthcare Trust With Outperform Rating, Announces Price Target of C$13.5
Raymond James Initiates Coverage On DRI Healthcare Trust With Outperform Rating, Announces Price Target of C$13.5
RBC Capital Maintains Outperform on DRI Healthcare Trust, Raises Price Target to C$16
UBS Initiates Coverage On DRI Healthcare Trust with Buy Rating, Announces Price Target of C$10
No Data